Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02PNP
|
|||
| Former ID |
DIB009713
|
|||
| Drug Name |
AGN-214868
|
|||
| Synonyms |
SXN-100323; SXN-323; Cell secretion inhibitors (pain), Syntaxin/Allergan; Modified bacterial protein therapies (pain), Allergan/Syntaxin; Clostridial endopeptidase-based compounds (pain), Allergan/Syntaxin; Neurotoxin-based technology (pain), CAMR/Allergan
Click to Show/Hide
|
|||
| Indication | Overactive bladder [ICD-11: GC50.0; ICD-10: N32.8] | Phase 2 | [1] | |
| Company |
Allergan
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01678924) A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.